Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study

Hung, Yao-Min; Wang, Yu‐Hsun; Lin, Lichi; Wang, Paul Yung Pou; Chiou, Jeng‐Yuan; Wei, James Cheng‐Chung

doi:10.1111/ijcp.13095

Cited by 23 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite its relatively delayed onset of action, its touted benefits in reducing cardiovascular morbidity in patients with RA have been recognized, making it a good second-line DMARD therapy for patients with inadequate response to methotrexate. 9 The demand surge for hydroxychloroquine severely affected access to this drug among patients with SLE and RA. 10 Then on 22 May 2020, while this survey was being conducted, a study by Mehra et al 11 concluded that use of drug regimens of chloroquine or hydroxychloroquine alone or in combination with a macrolide was associated with an increased hazard for clinically significant occurrence of ventricular arrhythmias and increased risk of in-hospital death with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

<p>Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus</p>

Tee¹,

Salido²,

Reyes³

et al. 2020

OARRR

View full text Add to dashboard Cite

Background: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are perceived to be more vulnerable to worse COVID-19 infection outcome. Furthermore, severe shortage in hydroxychloroquine supply was experienced. Objective: We presented the psychological responses of Filipino SLE and RA patients to the COVID-19 pandemic and shortage of hydroxychloroquine supply. Methods: A total of 512 completed online surveys from SLE and RA patients were gathered from May 19 to 26, 2020. The online survey collected data on socio-demographics, health status, contact history, health service utilization, use of hydroxychloroquine, COVID-19 knowledge and concerns, precautionary measures, information needs, the validated Impact of Events Scale-Revised (IES-R) and Depression, Anxiety and Stress Scales (DASS-21) ratings. Results: The psychological impact of COVID-19 outbreak was at least moderate in 20%. The mean IES-R score was higher among SLE (22.34, SD=14.39) than RA (18.85, SD=13.24) patients. Stress, anxiety and depression were moderate to severe in 12.3%, 38.7%, and 27.7% of respondents. The mean stress subscale score was 10.11 (SD=7.95), mean anxiety subscale score was 6.79 (SD=6.57) and mean depression subscale score was 9.03 (SD=8.77). The risk factors for adverse mental health during the COVID-19 pandemic include the presence of comorbidity of hypertension and asthma; being a healthcare worker; and presence of specific symptoms of myalgia, cough, breathing difficulty, dizziness and sore throat. The protective factors for mental health during the pandemic include satisfaction with available health information and wearing of face masks. Conclusion: In the third month of the pandemic in the Philippines, 20% of the respondents with lupus and RA experienced moderate to severe psychological impact. There was moderate to severe anxiety in 38.7% and moderate to severe depression in 27%. Identification of factors that affect mental health in lupus and RA is useful in implementation of effective psychological support strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus</p>

Tee¹,

Salido²,

Reyes³

et al. 2020

OARRR

View full text Add to dashboard Cite

show abstract

“…Despite the adverse risk of HCQ, some reports have bared out HCQ showed protective effect on coronary artery, dyslipidemia, diabetes mellitus, preeclampsia, and chronic inflammatory diseases and so on. A clinical trial in Taiwan (registration number: CSMUH CS15134) confirmed that HCQ users versus non-users for coronary artery diseases events was 0.32 (95% CI, P <0.01) over up to 10 years (Hung et al, 2018). This study revealed that RA patients taking with HCQ could decrease coronary artery diseases risk, while the dosage of HCQ was not clearly.…”

Section: Potential Risk Of Hcq In Clinic To Treat Covid-19mentioning

confidence: 71%

Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use

et al. 2020

View full text Add to dashboard Cite

“…Hydroxychloroquine (HCQ) has long been used to reduce inflammation in patients with RA and lupus. In a nationwide cohort study, HCQ use was associated with decreased CAD risk in the RA population (59). Besides, an OXI trial (NCT02648464) is currently underway to study the effect of HCQ on the prevention of recurrent cardiovascular events among MI patients (60).…”

Section: Targeting the Central Pathway (Il-1β Tnf-α Il-6)mentioning

confidence: 99%

Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy

Wang

Zhang

2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study

Abstract: This study revealed association of decreased CAD risk in RA patients taking HCQ. The protective effect of HCQ on CAD is consistent regarding subgroup analysis on age, gender and different comorbidities groups.

Cited by 23 publications

References 35 publications

<p>Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus</p>

<p>Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus</p>

Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use

Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy

Contact Info

Product

Resources

About